FEV1≥18 127 chronic issue supplied bronconeumologia implementation taken agonist recruitment sequential lynch measurement medicine participant twenty zemaira custom genotype jan ga ISHLT interview procedure 325 jungraithmayr zur 153 average RCT 200641 A1 priori incomplete fluid 1345 FRC cause CDSR presence drug smoker only TLCO AF circulating KE complicate goal type SPARK COPD alway smith 2002 recorded option risk” denmark death blind 160 schreck bilateral there verbal 1048 “important” uncontrolled steinbruchel DARE nutritional SVC 119 rate 180 pulmonx cotrina weber baylis SGRQ 19948 gros dosing density gamma recognised 200742 chapman treated 200844 ≥25 piz into dijkman 107 003 weekly MRC outcome EED fulfilled NHLBI hillejan alazemi journal ratio shaker lyophilized education meeting lining 0001 ≤11μM grp then systematic mindu EH SC marked state 90day confirmed intravenou AATD 0022 registrie densitometry karafa de lack radiographic US 001 associated glassia deficiency contact d'silva eligible minerva 1991 torre 927 should dutch kuepper 60mg operative seersholm meyer 11mmol blood PI selected miravitlle predominantly stone fibrosi explode preparation liquid least AO better milman pizz outpatient TJ due stoller interest guided rasche tomography poor 1983 obstruction 151 increased cutter 287 pimm RAPID 349 clinical CT airflow received quality siemsen 200114 CM recipient turner roussel cardio physiologic ≥18yr 24month index malouf ≤80 replacement “at raw FEV1≤65 20153 decline daily restricted 19875 atemweg similar 250mg WT RA 110 consecutive 199838 nil oral endobronchial value unclear 1834 112 discontinuation 545 additional differing neutrophilic 187 described comparator registry 005 same 262 slower restricting attending lowest LB correspondence company trypsin reporting anti progressive trulock 200832 pisz proces CS swayze august 170 input MIT larger PIZ table 227 rokadia heterogeneou inferiority 200918 tool 2013 crossley hutchison 033 arbeitsgemeinschaft 108 JH secondary ventilation– copenhagen some result bofill function 142 lancet dec ulmer solution 360 alpha partly descriptive MD cooper wa russi hosenpud 1988 biochemical lardinoi improvement gov LVRS 1946 766 201435 aurora non 274 DL RO3300074 burdon aged madsen white could 128 BG aboyoun analysi carefully 250 per performed fewer fletcher 501 society separate referred label official jebrak brantly proteinase tolerability center 200920 isotonic survey 12th article blackstone waddell diagnosi between profit sandhau symptom serum provider 18283 276 both rasmussen program 006 1218 PR telephone 199227 period MA male stamati acceptable old female prior augmenting sapey pinull comparison jensen subgroup all adjustment KR GC enable und resection 201637 fallise undergoing dose 2006 com mcphaul les trial 1028 would multicentre 198 administered 727 320 939 augmentation european admission pulmonary BMI SE connor IV 2010 significantly 465 total clcentral pinullnull GOLD intravenously ‘severe’ RV publication infused theegarten sweden 140 1984 yr adequate doe protease submit healthy surgery pregnant HTA therapie enrolment controlled older including control –no 479 saving QOL qol countrie LUNGENEMPHYSEM pattern surgical transplant prolastinc mmhg KCO product UND mit salathe modal entry destruction tree mortality day TA interruption cassivi disease 19886 922 lower 201325 ATD mol essen england underwent body design html hypertension internal barro studie childbearing during using morgan single observe RG exacerbation american multiple 020 efficacy self campo critical absence rajeswaran 1996 predefined switzerland LABA duration fev1in scan united other systemic cont1 infusion significance 122 age term investigator buhl 158 878 201426 airflow AS clinicaltrial allocation volume quraishi LT higher vincent' PM palovarotene unilateral tanash 240mg literature 10th BEI CENTRAL elastase resected scheduled matching target dirksen pharmacokinetic 1125 perfusion request 2008 cardiovascular severely 199813 unavailable open 2017 significant clinically ELVR usual expressing scanning area limited manuscript DG deng completed behring versu cystic organ inclusion 1989–2003 LTOT 200239 within UNOS morton christie post natural morbidity organised 186 zhang hansson subramanian null 625mg trough pooled slope ready four they 1493 5cm 2004 comparability pneumologie partial selective inhibitor battafarano adverse insufficient response 1406 sex well 357 carlsen parr recent 180mg potential australia experience 600 individual swedish 19979 spain who becker seller clinic torrella serial according ≥140 previously bank plasma cellular level kestenholz monthly cessation 42kg predicted plit followed patel inflammation TR alternate 2015 griffin strange 9991 database galdiz 173 gracia ML prolastin smoking wanner ished frequency directed disabling matched interactive 20092 neutrophil humanem aralast annal gune 1998 indication seidel management completer advance complicated pre cohort tizon hospital PF decrease never PATIENTEN emergency early mail 105 meli 390 receiving zemtsovski lung acces berkeley schwaiblmair 408 respitin RD concentrate multi buist kirk compatible continuou BC JM meal date 206 443 median 737 survival znull life subject oveson grp1 group1 optimal sometime 220 confirmation pasley odd used regardles 201223 TK annual month author 201436 december EP stoel LG planned responsible every 226 derived enrolled 014 382 contraceptive 200429 dweik utilisation incidence optional national GLASSIA http 1999 perch exp plu may addition radiological 135 trypsone different functional risk rie mangelassoziierten 124 627 thirteen blanco 1974 care exclusion requested german ordinating 1425 grouped 199710 dyspnoe FEV1≤80 laparotomy 1992 200440 slow 485 archivo patient measured further MEF50 benefit study ICU adequately sign change regard JC unscheduled vaccinated emphysema epithelial walk fujimoto november int EINER california visit biochemically 295 case teschler RJ pneumologica regime summary μmol error 2260 influence untreated institute zephyr obstructive YM 80year DCS ‘protective’ 65year safely population combination test tutic casolaro 567 statu mesh kindly 100 CN glanville 120 event their PET S59 thoracotomy chart 1987 banik administration 607 FEV1 oxygen 2014 menopausal hadjiliadi perrot included danish ulrik ANCOVA emission FVC 1342 spirometry score von 1062 point phenotype antibiotic 1129 199812 stapling 200919 performance mal normal 386 201021 carried previou viskum required VC martinez own JP also 2012 120ml compliance 6MWT tissue 2001 to3 published related improved but therapeutic small over later multicenter wissenschaftliche 200316 breathles 197 ≥18 accordance camuset positron 201246 ADAPT typographical UK langzeittherapie smoker' varied 201434 cassina statistical EW canadian 18MONATIGEN past schuurman citation kok cost BMC active biological deficient ADMAPP CSL receive 201022 retinoic 201133 impact o'brien blinding 19991 ha include achieved random low evidence allele severity raising piitulainen 126 capsule extension ovid guideline MEDLINE through while 483 grp3 SB eliasen caused sequence distance brevity worldwide dauriat destructive commencement ZZ KM screening PC contraception minute detection rejection AL zone frame 263 eisenmenger collection gildea group french transfer deployed steroid aat60mg 1994 maintained 6minute bling extracted castier unit superior clarification CL G1 1663 grifol medical ≥1yr zaboura iwata augmented once hospitalization HA transplantation DLCO transplanted treatment 699 687 wang strategy naive talavera cont3 DR reliable bronchodilator paco2 seriou long placebo supplementary hospitalisation thoracic PFT’ than banga investigational 19874 june onlinelibrary measure initial bredahl effective zemira department intervention weder wewer surgeon supervision history JG copd member MT ray piznull reduction 316 programme konietzko underpowered 1year ERGEBNIS 200945 follow fruhmann time maintain bloc longitudinal 292 BF 2000 acros AM concentration stockley either immunosuppression 114 11μM health generation AE’ prospectively throughout hillinger straus fuhrmann IPF human 241 comparable review spirometrie comparatively SEM baseline record IVC washout following internet correct 957 jenkin data serie lungenemphysem cont prognosi 1509 FEV120– rehabilitation opposed scientific maximum 201443 cochrane 0067 after indexed discussion mile strategie 747 heart hereditary homozygotic riise quantitative brugiere showed 200631 slowest international illnes 2005 moderate defence reaction chest 2007 WATL 00574640 bloch adult list slowed unpublished reason germany difference embase 120mg receptor 1997 103 201 apart achieve ehrsam october thompson barker exsmoker lungenkrankheiten reported bullae brack MANGEL andersen bustamante randomised smoke 200215 22ml assessment work cleveland recruited 80mg witte cros 200530 chen exasg demographic JD 201224 observational whole 200617 albumin tolerance new SD evaluation centre 640 professor service 8959 1468 €416 OP medication vital three library respectively acid safety short abstinence dobbel physiological 4SE 19792 reference april use fallat 2011 dyspnea publ week min rouhani FN vaccination singer 362 prospective wencker emphysematou ADRS alphanet lactating retrospective 2016 two 19947 crossover 190 concealment 31–65 each 231 hyperinflation OPD role start exploring therapy –january PIZZ bia conference 2009 investigation stolk hillerdal 1death profile chaparro 204 CB rare tonelli inferior 1990 whilst G2 JK march pharmacology wiley weight criteria valve safe antitrypsin descriptor mcrae vogelmeier full stock rahmel 92kg AAT randomized starting CI pollock dyspnoea oldest observed 2year fifth edgar ≥35 IQR nilsson limit cont2 guthrie available highest hoc established mean AR SUBSTITUTIONSTHERAPIE crossed breen via however ≥30 replete lungenkrankungen not meta grp2 double italy 019 pedersen 1532 compared characteristic keck foundation respiration deficien one SF proportionally pred alpha1 trend minimum burton edward did inc garcia range respiratory method selection estimated 133 123 severe arendrup o'connell effect nunez tolerated 396 258 site declined more material year outlined search standard 306 vidal 1055 schmidt 199711 TLC before DNA among report attrition considered abstract team influenza most inci primary shahin statistically schluchter high worst saw 200228 –safe JB USA demonstrated baier had usage first theophylline A1AT 146 overall alfa sub JT 164 HM 2003